Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | ELANE | P08246 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21672753 | 0.81 | SRC (0.35) | SRC | |
| SCHEMBL5493982 | 0.71 | MAPT (0.36) | SRCALDH1A1MAPT | |
| SCHEMBL5316693 | 0.71 | SRC (0.34) | SRCMAPT | |
| SCHEMBL26121351 | 0.71 | SRC (0.34) | SRCMAPT | |
| SCHEMBL12920665 | 0.71 | SRC (0.41) | SRCCYP3A4MEN1ALDH1A1MAPT | |
| SCHEMBL1565463 | 0.71 | OGG1 (0.31) | — | |
| SCHEMBL21672756 | 0.67 | SRC (0.44) | SRC | |
| SCHEMBL26119056 | 0.67 | SRC (0.32) | SRC | |
| SCHEMBL31055794 | 0.67 | MAPT (0.38) | SRCCYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL26122962 | 0.67 | SRC (0.32) | SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2404921-B1 | SALTS OF TETRAHYDROIMIDAZO[1,5-a]PYRAZINE DERIVATIVES, PREPARATION METHODS AND PHARMACEUTICAL USE THEREOF | JIANGSU HENGRUI MEDICINE CO (CN) | 2017-11-22 | — | — | EP | disclosed |
| EP-2230241-B1 | TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE DERIVATIVES, PREPARATION METHODS AND MEDICAL USES THEREOF | JIANGSU HENGRUI MEDICINE CO (CN) | 2014-11-26 | — | — | EP | disclosed |
| US-8518946-B2 | Salts of (R)-7-[3-amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-trifluoromethyl-5,6,7,8-tetrahydroimidazo[1,5-a] pyrazine-1-carboxylic acid, preparation method and medical use thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2013-08-27 | — | — | US | disclosed |
| US-8513411-B2 | Tetrahydro-imidazo[1,5-α] pyrazine derivatives, preparation process and medicinal use thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2013-08-20 | — | — | US | disclosed |
| US-20120220766-A1 | TETRAHYDRO-IMIDAZO[1,5-alpha] PYRAZINE DERIVATIVES, PREPERATION PROCESS AND MEDICINAL USE THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2012-08-30 | — | — | US | disclosed |
| US-8207161-B2 | Tetrahydro-imidazo[1,5-α]pyrazine derivatives, preparation process and medicinal use thereof | JIANGSU HENGRUI MEDICINE CO. LTD. (CN) | 2012-06-26 | — | — | US | disclosed |
| US-20120065209-A1 | TETRAHYDRO-IMIDAZO[1,5-a]PYRAZINE DERIVATIVES SALTS, PREPARATION METHODS AND MEDICINAL USE THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2012-03-15 | — | — | US | disclosed |
| EP-2404921-A1 | SALTS OF TETRAHYDROIMIDAZO Ý1,5-A¨PYRAZINE DERIVATIVES, PREPARATION METHODS AND PHARMACEUTICAL USE THEREOF | Jiangsu Hengrui Medicine Co., Ltd. (CN) | 2012-01-11 | — | — | EP | disclosed |
| US-20100273786-A1 | TETRAHYDRO-IMIDAZ0[1,5-A]PYRAZINE DERIVATIVES, PREPARATION PROCESS AND MEDICINAL USE THEREOF | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2010-10-28 | — | — | US | disclosed |
| EP-2230241-A1 | TETRAHYDRO-IMIDAZOÝ1,5-A¨PYRAZINE DERIVATIVES, PREPARATION METHODS AND MEDICAL USES THEREOF | Jiangsu Hengrui Medicine Co., Ltd. (CN) | 2010-09-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220766-A1 | TETRAHYDRO-IMIDAZO[1,5-alpha] PYRAZINE DERIVATIVES, PREPERATION PROCESS AND MEDICINAL USE THEREOF | DPP4, DPP3, DPP7 | SRC 2872/4885CYP1A2 79/4885CYP3A4 17/4885 |
| US-20120065209-A1 | TETRAHYDRO-IMIDAZO[1,5-a]PYRAZINE DERIVATIVES SALTS, PREPARATION METHODS AND MEDICINAL USE THEREOF | DPP4, DPP7, DPP3 | SRC 1638/4885CYP1A2 682/4885CYP3A4 26/4885 |
| US-20100273786-A1 | TETRAHYDRO-IMIDAZ0[1,5-A]PYRAZINE DERIVATIVES, PREPARATION PROCESS AND MEDICINAL USE THEREOF | DPP4, DPP7, DPP3 | SRC 2920/4885CYP1A2 103/4885CYP3A4 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.